These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439 [TBL] [Abstract][Full Text] [Related]
3. Troglitazone inhibits histone deacetylase activity in breast cancer cells. Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment. Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712 [TBL] [Abstract][Full Text] [Related]
5. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Davies GF; Juurlink BH; Harkness TA Drug Des Devel Ther; 2009 Sep; 3():79-88. PubMed ID: 19920924 [TBL] [Abstract][Full Text] [Related]
6. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Misra R; Sahoo SK Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667 [TBL] [Abstract][Full Text] [Related]
7. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related]
8. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance. Skildum A; Dornfeld K; Wallace K Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112 [TBL] [Abstract][Full Text] [Related]
9. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition. Gao M; Xu Y; Qiu L J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110 [TBL] [Abstract][Full Text] [Related]
10. Gallic acid enhances pirarubicin‑induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P‑glycoprotein inhibition. Aye KT; Wattanapongpitak S; Supawat B; Kothan S; Udomtanakunchai C; Tima S; Pan J; Tungjai M Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34476509 [TBL] [Abstract][Full Text] [Related]
11. Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia. Zhang G; Fang L; Zhu L; Zhong Y; Wang PG; Sun D J Med Chem; 2006 Mar; 49(5):1792-9. PubMed ID: 16509594 [TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle. Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184 [TBL] [Abstract][Full Text] [Related]
14. [Down-Regulation of MiR-125b Reverses Drug Resistance of Doxorubicin-Resistant Leukemia Cells]. Deng YM; Luo AL; Li GF; Cai MS; Xu L; Yan MX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1610-1615. PubMed ID: 30501692 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells. Chen Y; Zhao Y; Wang C; Xiao X; Zhou X; Xu G Med Sci Monit; 2012 Oct; 18(10):BR383-8. PubMed ID: 23018344 [TBL] [Abstract][Full Text] [Related]
16. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176 [TBL] [Abstract][Full Text] [Related]
17. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells. Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268 [TBL] [Abstract][Full Text] [Related]
18. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway. Wang Z; Yang L; Xia Y; Guo C; Kong L Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987 [TBL] [Abstract][Full Text] [Related]
20. Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox? Hu X; Yang H; Pan QR; Zheng S Chemotherapy; 1995; 41(4):296-305. PubMed ID: 7555211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]